Phreesia, Inc. (NYSE:PHR) Given Consensus Recommendation of “Buy” by Brokerages

Phreesia, Inc. (NYSE:PHR) has received a consensus recommendation of “Buy” from the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. Twelve investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $31.33.

Several research analysts recently issued reports on the stock. Truist Financial raised their target price on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Robert W. Baird reduced their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and issued a $33.00 price target (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. Finally, Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th.

Phreesia Stock Down 1.6 %

Phreesia stock opened at $25.57 on Tuesday. The business’s 50-day simple moving average is $27.35 and its two-hundred day simple moving average is $24.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The company has a market cap of $1.50 billion, a PE ratio of -17.40 and a beta of 1.03. Phreesia has a fifty-two week low of $17.07 and a fifty-two week high of $30.53.

Insider Transactions at Phreesia

In other Phreesia news, CFO Balaji Gandhi sold 1,827 shares of Phreesia stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $27.46, for a total transaction of $50,169.42. Following the transaction, the chief financial officer now directly owns 103,591 shares of the company’s stock, valued at $2,844,608.86. The trade was a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Amy Beth Vanduyn sold 1,311 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total value of $34,885.71. Following the completion of the transaction, the senior vice president now owns 115,633 shares of the company’s stock, valued at $3,076,994.13. The trade was a 1.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 164,269 shares of company stock valued at $4,661,469. Corporate insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Johnson Financial Group Inc. lifted its position in shares of Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock worth $28,000 after purchasing an additional 896 shares in the last quarter. R Squared Ltd purchased a new stake in Phreesia during the 4th quarter worth approximately $30,000. BankPlus Trust Department acquired a new stake in Phreesia during the 4th quarter worth approximately $34,000. Quarry LP boosted its position in Phreesia by 210.9% in the 4th quarter. Quarry LP now owns 2,835 shares of the company’s stock valued at $71,000 after buying an additional 1,923 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in Phreesia in the 4th quarter valued at approximately $76,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.